Kobo Biotech Ltd (KOBO) — shareholding pattern, promoter holding, financials and share price
About Kobo Biotech Ltd (KOBO)
Kobo Biotech Ltd operates in the Commodity Chemicals industry, within the Chemicals sector. It trades on the NSE as KOBO and on the BSE under scrip code 531541. Its ISIN is INE881A01015.
Incorporated in 1993, Kobo Biotech Ltd is in the pharmaceutical business [1]
Kobo Biotech Ltd. is a key player in the pharmaceutical sector, focusing on the production of active pharmaceutical ingredients (API).
The company possesses significant expertise in diketene chemistry, with manufacturing facilities in Andhra Pradesh supporting diverse applications in pigments, pharmaceuticals, and pesticides.
Listed peers in Commodity Chemicals: Caprolactam Chemicals Ltd, Asian Petroproducts & Exports Ltd, Pentokey Organy (India) Ltd, Vinyoflex Ltd, Advance Petrochemicals Ltd, TECIL Chemical & Hydro Power Ltd.
Valuation & Returns
10 Jul 2026At ₹9.09 a share on 10 Jul 2026, Kobo Biotech Ltd (KOBO) was valued at a price-to-earnings ratio of -4.3x against an industry P/E of 45.11x. Solomo computes return on equity of 3.71% and return on capital employed of -324.95% from filed results. Earnings ratios use standalone results for the twelve months Sep 2023 to Jun 2024.
- P/E
- -4.3x
- Industry P/E
- 45.11x
- EPS (TTM)
- ₹-2.12
- Book value / share
- ₹-57.98
- ROE
- 3.71%
- ROCE
- -324.95%
- ROA
- -7.04%
- Debt / equity
- -1.05x
- Dividend yield
- 0%
- 52-week range
- ₹1.99 – ₹9.09
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2015In the year ended Mar 2015, Kobo Biotech Ltd (KOBO) reported revenue of ₹103 crore, net profit of ₹-35 crore and earnings per share of ₹-15.48. That compares with revenue of ₹103 crore and net profit of ₹-35 crore in Mar 2014. Figures are consolidated, as filed with the exchanges.
In the quarter ended Jun 2024, net profit ₹-1.33 crore (standalone).
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 162 | 287 | 404 | 103 | 103 |
| Net profit (₹ cr) | 10 | 16 | 14 | -35 | -35 |
| EPS (₹) | 4.37 | 6.72 | 6.22 | -15.48 | -15.48 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | - | - | - | -74.87% |
| Profit growth | - | - | - | -6.09% |
| Stock price CAGR | 0% | 8% | 62% | 281% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 44.95% of Kobo Biotech Ltd (KOBO) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0%. Market capitalisation was ₹22 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: SANJAY LUTHRA 1.06%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 44.95% | - | - | 0% | 55.05% |
| Mar 2026 | 44.95% | - | - | 0% | 55.05% |
| Dec 2025 | 44.95% | - | - | 0% | 55.05% |
| Sep 2025 | 44.95% | - | - | 0% | 55.05% |
| Jun 2025 | 44.95% | - | - | 0% | 55.05% |
| Mar 2025 | 44.95% | - | - | 0% | 55.05% |
| Dec 2024 | 44.95% | - | - | 0% | 55.05% |
| Sep 2024 | 44.95% | - | - | 0% | 55.05% |